Sanofi Faces 1st US Suit Over Likely Carcinogen In Zantac

Law360 (September 16, 2019, 6:00 PM EDT) -- A Florida man with breast cancer has accused Zantac maker Sanofi Aventis US LLC of knowingly selling a medication that contained a probable carcinogen in the first suit of its type in the U.S.

Joseph L. Galimidi told a Florida state court Monday that testing found that individual doses of Zantac, the brand name for the heartburn medication Ranitidine, contain more than 3 million nanograms of N-Nitrososdimethylamine, or NDMA, while the U.S. Food and Drug Administration has established a daily limit of 96 nanograms.

The suit comes shortly after the FDA issued a warning that NDMA was found in Zantac at...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS